Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: RXGOLF who wrote (27990)	2/7/1999 8:02:00 PM
From: Henry Niman	Respond to of 32384

Greg, If pre-clinical reprints can be handed out, then I suspect that LGND's sales force as well as the various publishers reprints department will be quite busy. LGND, like most of the well established biotechs, encourages scientists and collaborators to publish, especially if the require patents have been previously filed. To enter a trial, extensive pre-clinical work must be preformed and such work is generally "publishable" in peer review journals. LGND of course already has many published reports demonstrating various pre-clinical applications of their drugs.